Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$11.75 ▲ +0.47
(+4.17%)
MKT CAP: $2.63B • VOL: 2.74M
52W L $7 52W H $20
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$10
MEDIAN
$13
MEAN
$13
HIGH
$16
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE ADMA TAPE
ADMA // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $14.22 | $13.51 | 2025-02-14 | $10.69 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $14.80 | $13.86 | 2025-02-06 | $11.04 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $13.39 | $12.93 | 2025-01-29 | $11.28 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $11.98 | — | 2025-01-17 | $11.52 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $10.34 | $11.16 | 2025-01-09 | $10.46 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $13.98 | $12.22 | 2024-12-18 | $10.22 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $11.40 | $11.87 | 2024-12-04 | $10.93 | -4.3% | 48% | C |